OCGN
$2.45
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene thera...
Recent News
Why Ocugen (OCGN) Is Up 54.0% After OCU400 Phase 3 Progress And Going Concern Spotlight
Ocugen, Inc. previously secured shareholder approval to increase authorized common shares, corrected a voting-power error in its Series C Preferred Stock designation, reported higher full-year net loss of US$67.85 million on US$4.41 million revenue for 2025, filed a US$23.24 million shelf registration, and received an auditor going concern warning, while advancing its OCU400 Phase 3 program toward planned 2026–2027 regulatory milestones. At the same time, Oppenheimer’s new research coverage...
How Ocugen (OCGN) Phase 2 And Phase 3 Milestones Are Reframing The Investment Story
Ocugen’s updated fair value estimate of US$10.36 per share, up from US$9.00, has pushed the price target conversation back into focus for many investors. Analysts linking this change to the latest OCU410 Phase 2 readout and OCU400’s progress into Phase 3 are splitting into more bullish and more cautious camps, each with its own view on how these programs fit the updated valuation range that runs from about US$10 to US$22. As you read on, you will see how to follow this evolving narrative and...
Midday Fly By: IEA to release 400M oil barrels, Oracle reports Q3 beat
The major averages were lower near noon, with the Dow dropping over 400 points as traders weigh shifting oil prices and a key inflation report. Markets are trading cautiously amid volatile energy prices and ongoing geopolitical tensions in the Middle East. Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Oil prices, which spiked
Oppenheimer Starts Ocugen (OCGN) at Outperform on Gene Therapy Pipeline
Oppenheimer initiated coverage of Ocugen (NASDAQ:OCGN) with an Outperform rating and a $10 price target on Wednesday, positioning the clinical-stage gene therapy company as an emerging leader in blinding ocular disorders. The call arrives just days after Ocugen completed enrollment in its Phase 3 retinitis pigmentosa trial and reported full-year 2025 financials that reflected both ... Oppenheimer Starts Ocugen (OCGN) at Outperform on Gene Therapy Pipeline
Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year?
Here is how ArriVent BioPharma, Inc. (AVBP) and Ocugen (OCGN) have performed compared to their sector so far this year.